Coreyann Fluker
Family · Monroeville, PANPI 1467965236
Payments from drug & device makers
Across 1,114 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Otsuka America Pharmaceutical, Inc.$2K
- Novo Nordisk$2K
- Alkermes, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- plus $9K from 43 others
What the payments were for
- Food & beverage$20,03799%
- Education$1321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,170 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 139 | $154,868 |
| JardianceEmpagliflozin | 78 | $76,683 |
| VraylarCariprazine Hcl | 43 | $67,049 |
| TrulicityDulaglutide | 63 | $66,671 |
| MounjaroTirzepatide | 55 | $57,134 |
| RexultiBrexpiprazole | 36 | $51,617 |
| EliquisApixaban | 64 | $49,617 |
| FarxigaDapagliflozin Propanediol | 32 | $31,392 |
| RybelsusSemaglutide | 17 | $26,338 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $16,038 |
| TrintellixVortioxetine Hydrobromide | 30 | $14,274 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 11 | $14,021 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 90 | $11,345 |
| TradjentaLinagliptin | 11 | $8,670 |
| Spiriva RespimatTiotropium Bromide | 14 | $6,929 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $1,670 | $195,227167 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $402 | $123,805118 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $227 | $92,282103 claims |
| AbbVieVraylar | $3,011 | $67,04943 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,390 | $51,61736 claims |
| PfizerEliquis | $227 | $49,61764 claims |
| AstraZenecaFarxiga, Symbicort | $521 | $34,73646 claims |
| GSKTrelegy Ellipta, Lamictal | $109 | $21,68941 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $721 | $14,27430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.
Other family in Monroeville
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.